Editorial
doi: 10.1093/jnci/88.24.1791.
Five years of tamoxifen--or more?
- PMID: 8961965
- DOI: 10.1093/jnci/88.24.1791
Item in Clipboard
Editorial
Five years of tamoxifen--or more?
J Natl Cancer Inst.
.
No abstract available
Comment on
-
Recent trends in U.S. breast cancer incidence, survival, and mortality rates.J Natl Cancer Inst. 1996 Nov 6;88(21):1571-9. doi: 10.1093/jnci/88.21.1571. J Natl Cancer Inst. 1996. PMID: 8901855
-
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.J Natl Cancer Inst. 1996 Dec 18;88(24):1828-33. doi: 10.1093/jnci/88.24.1828. J Natl Cancer Inst. 1996. PMID: 8961972 Clinical Trial.
-
Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.J Natl Cancer Inst. 1996 Dec 18;88(24):1834-9. doi: 10.1093/jnci/88.24.1834. J Natl Cancer Inst. 1996. PMID: 8961973 Clinical Trial.
Similar articles
-
The duration of adjuvant tamoxifen therapy.Cancer Treat Res. 1998;94:181-93. doi: 10.1007/978-1-4615-6189-7_10. Cancer Treat Res. 1998. PMID: 9587688 Review. No abstract available.
-
Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: mortality over 10 years.J Natl Cancer Inst. 1999 Jul 7;91(13):1167-8. doi: 10.1093/jnci/91.13.1167. J Natl Cancer Inst. 1999. PMID: 10393732 No abstract available.
-
[For how long should breast cancer patients take Tamoxifen? The International Program ATLAS will answer this question].Vopr Onkol. 1998;44(4):373-7. Vopr Onkol. 1998. PMID: 9807196 Russian. No abstract available.
-
Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.J Natl Cancer Inst. 1996 Dec 18;88(24):1828-33. doi: 10.1093/jnci/88.24.1828. J Natl Cancer Inst. 1996. PMID: 8961972 Clinical Trial.
-
[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed].Gan To Kagaku Ryoho. 1997 Aug;24(10):1203-9. Gan To Kagaku Ryoho. 1997. PMID: 9279337 Review. Japanese.
Cited by
-
Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer.South Asian J Cancer. 2018 Apr-Jun;7(2):142-145. doi: 10.4103/sajc.sajc_122_18. South Asian J Cancer. 2018. PMID: 29721482 Free PMC article.
-
The changing global patterns of female breast cancer incidence and mortality.Breast Cancer Res. 2004;6(6):229-39. doi: 10.1186/bcr932. Epub 2004 Aug 26. Breast Cancer Res. 2004. PMID: 15535852 Free PMC article. Review.
-
Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality.BMJ. 2000 Sep 16;321(7262):665-9. doi: 10.1136/bmj.321.7262.665. BMJ. 2000. PMID: 10987769 Free PMC article.
-
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
-
Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.J Cancer Res Clin Oncol. 2023 Feb;149(2):721-735. doi: 10.1007/s00432-022-04369-4. Epub 2022 Dec 20. J Cancer Res Clin Oncol. 2023. PMID: 36538148 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
